Sobrera Pharma completes oversubscribed financing round
The round exceeds SEK 20 million target, attracting international investors. Funds support SO-001 development toward Phase 2b readiness.
See the latest news and media coverage for Sobrera. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing addiction treatments
sobrera.comLast updated
In short: Sobrera Pharma completed an oversubscribed financing round and published positive Phase 2 results for its alcohol use disorder treatment, SO-001.
The round exceeds SEK 20 million target, attracting international investors. Funds support SO-001 development toward Phase 2b readiness.
Appointments bring commercialization and industrial expertise ahead of 2026 milestones. Chairman and CEO highlight strengthened leadership for execution phase.
Prof. Bo Söderpalm and Dr. Andrea de Bejczy discuss positive outcomes in Alcohol Use Disorder, published in The Lancet Regional Health Europe in July 2025.
Randomized double-blind placebo-controlled multicentre trial assesses efficacy and safety alone and combined for alcohol use disorder.
Track Sobrera and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.